ADVFN1 个月
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Nusinersen is currently commercialized ... followed by maintenance dosing every four months thereafter. SPINRAZA is an antisense oligonucleotide (ASO) that targets the underlying cause of motor ...
来自MSN1 个月
Sanofi taps Alloy Therapeutics for CNS antisense drug development
Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... Biogen’s ASO Spinraza (nusinersen) approved for spinal muscular ...
manilatimes1 个月
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Nusinersen is currently commercialized under the brand name SPINRAZA in over ... followed by maintenance dosing every four months thereafter. SPINRAZA is an antisense oligonucleotide (ASO) that ...